This study was designed to analyze the effect of global and gene-specific DNA methylation patterns on the outcome of patients with acute myeloid leukemia (AML). Methylation of CDKN2B (p15), E-cadherin (CDH) and hypermethylated in cancer 1 (HIC1) promoters and global DNA methylation by luminometric methylation assay (LUMA) was analyzed in 107 AML patients and cytogenetic and molecular mutational analysis was performed. In addition, genome-wide promoterassociated methylation was assessed using the Illumina HumanMethylation27 array in a proportion of the patients. Promoter methylation was discovered in 66, 66 and 51% of the patients for p15, CDH and HIC1, respectively. In multivariate analysis, low global DNA methylation was associated with higher complete remission rate (hazard ratio (HR) 5.9, P ¼ 0.005) and p15 methylation was associated with better overall (HR 0.4, P ¼ 0.001) and disease-free survival (HR 0.4, P ¼ 0.016). CDH and HIC1 methylation were not associated with clinical outcome. Mutational status and karyotype were not significantly associated with gene-specific methylation or global methylation. Increased genome-wide promoter-associated methylation was associated with better overall and disease-free survival as well as with LUMA hypomethylation. We conclude that global and gene-specific methylation patterns are independently associated with the clinical outcome in AML patients.
Introduction
Acute myeloid leukemia (AML) is a hematological malignancy with frequent and nonrandom genetic changes. Chromosomal translocations and gene mutations distinguish subtypes of the disease and have a role in proliferation and differentiation and also affect prognosis in AML. 1, 2 Epigenetic modification of DNA is an important biological function regulating gene expression in normal and tumor cells. Decrease in the whole-genome methylation level is widespread in neoplastic diseases. 3, 4 Methylation of promoter-specific CpG islands, and hence silencing of tumor suppressor and cell cycle control genes, is considered to be an important step in tumor development and has been shown previously in AML. 5 In one large study estrogen receptor methylation has been shown to correlate with better overall survival (OS) in AML. 6 Although methylation of other genes has been shown to associate with prognosis, the results are somewhat contradictory. [7] [8] [9] In high-risk myelodysplastic syndrome (MDS) and in AML after MDS, methylation of CDKN2b (p15), E-cadherin (CDH) and hypermethylated in cancer 1 (HIC1) have recently been shown to be associated with failure to achieve complete remission (CR) after induction chemotherapy. 10 We analyzed gene-specific promoter methylation of p15, CDH and HIC1 as well as global DNA methylation using the luminometric methylation assay (LUMA) technique in a well-characterized cohort of 107 AML patients. Furthermore, we examined genome-wide CpG island-associated promoter methylation of 27 578 promoter CpG sites, corresponding to 14 495 individual genes, in 20 AML patients using the Illumina HumanMethylation27 BeadChip. We found that low global LUMA methylation levels correlated with an increased CR rate and that methylation of p15 correlated with better disease-free survival (DFS) and OS in uni-and multivariate analyses. There was a correlation between less global LUMA methylation and increased genome-wide promoter-associated methylation using the Illumina array. We found no significant associations between the methylation pattern and the cytogenetic risk groups or the mutation status of FLT3 (Fms-like tyrosine kinase 3), NPM1 (nucleophosmin), CEBPA (CCAAT enhancer binding protein-a) and NRAS (neuroblastoma RAS viral oncogene homolog).
Materials and methods

Patients and sampling
A total of 107 previously untreated AML patients treated at the Karolinska University Hospital at Huddinge were included in the study. Patients with AML M3 or a previous history of MDS were excluded. Standard induction chemotherapy including cytarabine and an anthracycline was given aiming at CR. Patients who achieved CR were given standard consolidation therapy according to the applicable national or study protocol including allogeneic stem cell transplantation (n ¼ 23). Of all patients reaching CR, 18 (24%) received allogeneic stem cell transplantation, 41 (54%) received full consolidation therapy and 16 (22%) received reduced chemotherapy consolidation because of treatment toxicities. For diagnosis and classification of CR and progression, World Health Organization criteria were applied.
11 DNA was extracted from the diagnostic bone marrow samples (n ¼ 79) or peripheral blood (n ¼ 28) after mononuclear cell isolation (Lymphoprep; Axis-Shield PoC, Oslo, Norway). Informed consent was obtained before the specimens were collected. The study was approved by the regional ethics committee. Chromosome banding was performed using standard laboratory techniques. Mutation analyses of FLT3 (internal tandem duplications and tyrosine kinase domain mutations at codon D835 and I836), NPM1, CEBPA, and NRAS were performed as previously described. 12 Patients were divided into three age groups before multivariate analysis (o55, 55-75 and 475 years), and into three cytogenetic risk groups. In all, 5 patients had a low-risk karyotype (t(8;21), inv 16), 77 had intermediate-risk karyotype (normal karyotype and aberrations not defined as high or low risk) and 25 had a high-risk karyotype (del 7, del 5q, inv 3, t(6;9), complex (X5 aberrations)). The low-and intermediate-risk groups were analyzed together as there were too few samples in the lowrisk group to allow for meaningful multivariate analysis.
Bisulfite treatment and PCR
DNA was modified with sodium bisulfite as previously described. 13 A total of 2.5 mg of DNA from each sample was denatured in NaOH for 15 min at 37 1C, followed by incubation in sodium bisulfite at 55 1C for 16 h. Thereafter, DNA was recovered using the GeneClean II kit (Qbiogene, Montreal, QC, Canada), desulfonated in NaOH and precipitated in ethanol. PCR specific for bisulfite-reacted p15, CDH and HIC1 promoters was carried out in a final volume of 25 ml containing 50-100 ng of bisulfite-modified DNA, 1 Â TEMPase PCR Buffer (Bie & Berntsen AS, Herlev, Denmark), 0.2 mmol/l deoxyribonucleotide triphosphate (ABgene, Epsom, UK), 0.5 mmol/l each of forward and reverse primers 14 
Methylation analysis by DGGE
PCR products of bisulfite-reacted p15, CDH and HIC1 promoter regions were analyzed using denaturing gradient gel electrophoresis (DGGE) according to previously published protocols. 14, 15 In brief, the PCR products were loaded on a 10-70% denaturant gradient gel together with a fully methylated control (In vitro methylated DNA) and an unmethylated control (peripheral blood lymphocytes). After electrophoresis, gels were stained in Tris/EDTA buffer containing ethidium bromide and photographed under ultraviolet transillumination. Samples were scored as methylated when bands or smears were present on the gels in the area below the band corresponding to unmethylated DNA as reported in previous publications. 14, 15 Bisulfite pyrosequencing Pyrosequencing of the p15 promoter region was performed using the PSQHS96 system (Biotage AB, Uppsala, Sweden) including PyroGold reagents as previously described. 
Methylation-specific melting curve analysis
Methylation-specific melting curve analysis was performed as previously described for p15, CDH and HIC1 promoters, using the same primer pairs and PCR conditions as for DGGE. 17 Global DNA methylation assay by LUMA Global DNA methylation was quantified using LUMA as previously described. 18, 19 A total of 500 ng genomic DNA was cleaved with HpaII þ EcoRI or MspI þ EcoRI in separate reactions. After the digestion step, the extent of cleavage was quantified by pyrosequencing. HpaII and MspI are methylationsensitive isoschizomers. DNA methylation was defined from the HpaII/MspI ratio: fully methylated DNA gives a ratio that approaches 0 whereas if methylation is completely absent the ratio approaches 1. The assay was carried out in duplicate.
Illumina HumanMethylation27 Beadchip array
A total of 20 samples were also evaluated for genome-wide promoter methylation using the Illumina Infinium HumanMethylation27 Bead array. This analysis was made at the Bioinformatics and Expression Analysis core facility at the Karolinska Institute. The EZ DNA methylation kit (Zymo Research, Orange, CA, USA) was used for bisulfite conversion of 500 ng of DNA, and the remaining assay steps were performed as previously published using Illumina-supplied reagents and conditions. 20, 21 The Illumina Infinium II Bead Array uses allele-specific annealing to either methylation-specific probes or non-methylation probes to detect the methylation grade of 27 578 individual CpG sites spread across the promoter regions of 14 495 genes.
Statistical analysis
Categorical clinical parameters and gene-specific variables were analyzed in relation to CR by chi-square analyses or Fisher's exact test when appropriate. LUMA global methylation values were dichotomized at median. The contribution of gene promoter methylation and global methylation to DFS and OS were assessed using the Kaplan-Meier method and compared with the log-rank test. Binary logistic regression was used for multivariate analysis of CR. Cox regression analysis was used for multivariate analysis of DFS and OS. Correlations were calculated with Pearson's correlation for continuous variables and Spearman's r for ordinal data. Multiple-group comparisons were made using one-way analysis of variance. Statistical calculations were performed using the SPSS 16.0 software (SPSS Inc., Chicago, IL, USA) except for array analysis. The Beadstudio 2.0 software (Illumina Inc, San Diego, CA, USA) was used to normalize the results of the Illumina Infinium assay. Normalization was made by subtracting the average signal of the 700 negative controls from the probe signals. Differential methylation analysis and construction of a volcano plot was performed using the R statistical software package (www.r-project.org/) by applying a t-test error model. CpG sites with a detection P-value of 40.0001 were removed from analysis (n ¼ 244). All P-values are two sided.
Results
Patient characteristics
The study included 107 AML patients: 66 males and 41 females. Median age was 65.4 years (23-85 years). Nine patients had therapy-related AML and 98 were de novo AML. Baseline characteristics including molecular and cytogenetic characteristics are shown in Table 1 .
Results of DGGE and LUMA methylation analysis
DGGE showed methylation of the p15 gene promoter in 69 (66%) of the evaluable AML cases (Table 2 ). In all, 69 (66%) of the patients were methylated in the CDH promoter and 57 (51%) in the HIC1 promoter. There was a correlation between methylation of p15 and methylation of HIC1 (R ¼ 0.33, P ¼ 0.001) but not between p15 and CDH or CDH and HIC1 (P ¼ 0.38, P ¼ 0.94). The global DNA methylation levels as assessed by LUMA had a slightly left-skewed normal distribution pattern among the cases (Supplementary Figure 1) . Age or sex had no statistically significant effect on global LUMA methylation levels. There was no difference in gene-specific or global LUMA methylation levels between samples from peripheral blood or bone marrow (data not shown). Groups with different induction treatment protocols did not differ significantly regarding the primary outcome variables, LUMA (P ¼ 0.5), p15 (P ¼ 0.5), HIC (P ¼ 0.2) or CDH methylation (P ¼ 0.6). Neither did consolidation regimens, including whether the patients received allogeneic stem cell transplantation or reduced chemotherapy consolidation, differ in LUMA (P ¼ 0.5), p15 (P ¼ 0.8), HIC (P ¼ 0.9) or CDH methylation rates (P ¼ 0.6). Individual results for all experimental analyses and simple outcome variables are shown in Supplementary Table 1 and representative examples of DGGE and LUMA in Figure 1 .
Validation of DGGE by bisulfite pyrosequencing and methylation-specific melting curve analysis
To validate the DGGE results, bisulfite pyrosequencing of the p15 promoter was performed in 29 of the samples. Pyrosequencing was concordant with DGGE in 23 out of 29 samples (79%, P ¼ 0.003). The discordant samples were four cases methylated by DGGE but considered negative by pyrosequencing, and two cases unmethylated by DGGE but positive by pyrosequencing. The eight samples evaluated with methylation-specific melting curve analysis for p15, CDH and HIC1 results were 100% concordant with DGGE. Examples of pyrosequencing results are shown in Figure 1 .
Comparison of LUMA and Illumina whole-genome methylation assays
In 20 of the AML samples, methylation status of 27 578 mainly promoter associated CpG sites, corresponding to 14 495 genes, was analyzed using the Illumina HumanMethylation27 BeadChip whole-genome assay. The methylation profile in the whole cohort was bimodal, as shown in Figure 2a . To minimize overlap between the two distributions, a cutoff at b40.5 was set to consider a CpG site hypermethylated. Global methylation, as assessed by LUMA, showed an inverse correlation with the number of hypermethylated promoter CpG residues, as assessed by the Illumina array, Pearson's correlation 0.627, P ¼ 0.003 (Figure 2b ). A volcano plot shows the imbalance with more promoter-associated methylation in samples hypomethylated globally according to LUMA (Figure 2c ), verifying an inverse correlation between global hypomethylation and promoter CpG island hypermethylation. Table 2 ). We also performed a subgroup analysis of different age groups showing the relationship between LUMA and CR to be age dependent (Figures 3b and c) . Among patients younger than median age (65 years), 26 out of 27 (96%) with low global LUMA methylation levels achieved CR when compared with 17 out of 24 (61%) with high global LUMA methylation (P ¼ 0.02).
In patients older than 65 years of age, there was no difference (66 vs 61%, P ¼ 0.7). The better CR rates among patients with low global LUMA methylation did not translate into better DFS or OS in the whole cohort (P ¼ 0.6 and 0.9, respectively, Figure 3d ). However, for patients younger than 65 years, we found that OS and DFS were significantly better (P ¼ 0.005 and 0.04, respectively) among patients with low global LUMA methylation (Figure 3e ).
Methylation of p15 is associated with better DFS and OS
There were no differences in CR rates between patients with methylated and unmethylated p15 (55/69 vs 24/35, P ¼ 0.2). The DFS was significantly longer in patients with methylated p15, with a median of 30 months when compared with 12 months for cases with unmethylated p15 (P ¼ 0.03; Figure 4a ). The median OS was 23 compared with 11 months (P ¼ 0.01; Figure 4b ). In a Cox regression analysis using the same risk factors as in the logistic regression analysis above, p15 remained an independent prognostic factor for DFS (HR 0.44, 95% CI 0.23-0.86, P ¼ 0.02) and OS (HR 0.41, 95%CI 0.24-0.71, P ¼ 0.001; 
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=0.916 =2.136 Figure 1 Representative examples of (a) denaturing gradient gel electrophoresis. PBL is DNA from peripheral blood monocytes, the negative control. SSSI is SSSI-treated DNA, the positive control. Patient 1 is considered positive, 2 is negative and 3 is positive for DNA methylation. Prognostic implications of DNA methylation in AML S Deneberg et al confirmed the association between p15 methylation and survival (data not shown). HIC1 methylation showed no statistically significant association with CR. OS was better in HIC1 methylated cases in univariate analysis (median 23 vs 11 months), but there were no statistically significant associations between HIC1 methylation and OS or DFS in multivariate analysis (data not shown). There were no differences in clinical outcomes between patients with methylated and unmethylated CDH (data not shown).
Increased genome-wide promoter hypermethylation is associated with better DFS and OS
As our results suggested that increased gene-specific methylation of the p15 promoter is associated with better outcome, we also analyzed whether genome-wide promoter hypermethylation was associated with CR rate, DFS or survival. Cases were dichotomized at median into two groups by the number of hypermethylated (b40.5) CpG sites according to the Illumina array. There were no significant differences in age, cytogenetic or molecular risk factors between the groups. CR rates did not differ between the groups, but the DFS was significantly longer in patients with more hypermethylation, with median not reached compared with 4 months for cases with less hypermethylation (P ¼ 0.02; Figure 4c ). The median OS was not reached compared with 6 months (P ¼ 0.005; Figure 4d ). These results suggest that not only increased p15 promoter methylation, but also genome-wide promoter-associated hypermethylation in general is associated with improved survival.
Associations between methylation status and genetic abnormalities
We also studied the relation between gene-specific methylation as well as global methylation by LUMA in relation to molecular and cytogenetic status of the AML cells. Table 3 shows the results in patients subdivided according to cytogenetic and molecular status. Although some associations could be shown, after Bonferroni correction, all associations were found to be nonsignificant. Figure 3 CR rates are higher in patients whose samples show global hypomethylation. The pie charts show CR rates in samples with global methylation levels higher than median ('global DNA hypermethylation') and global methylation levels lower than median ('global DNA hypomethylation'). (a) The whole AML cohort (P ¼ 0.05), (b) the same data for AML patients younger than 65 years (P ¼ 0.02) and (c) for AML patients older than 65 years (P ¼ 0.7). (d) Overall survival (P ¼ 0.9) and disease-free survival (P ¼ 0.6) in the whole AML cohort according to high or low global DNA methylation by LUMA. (e) In patients younger than 65 years, OS (P ¼ 0.005) and DFS (P ¼ 0.04) were significantly better in samples with low global LUMA methylation levels. Patients were censored at the time of allogeneic stem cell transplantation.
p15, HIC1 and CDH methylation, as well as that of global DNA methylation, in a large cohort of genetically and clinically welldefined AML patients undergoing induction chemotherapy. The analysis was performed to study the effect of methylation on clinical outcome and response to therapy as well as its relation to genetic subtypes of AML. We also performed an analysis of genome-wide promoter-associated methylation using Illumina HumanMethylation27 BeadChip array technology in a subset of 20 patients.
Important novel observations in this study are the associations between global DNA methylation as well as p15 promoter methylation and clinical outcome. Other novel findings were the prognostic significance of the number of hypermethylated CpG sites as measured by Illumina Infinium for DFS and OS as well as the inverse association between global DNA methylation and genome-wide promoter methylation.
Our data suggest the existence of a subset of AML cases with good prognosis, characterized by low global DNA methylation levels paired with increased p15 methylation as well as genomewide promoter-associated methylation levels, mainly discernable in younger patients.
Global DNA hypomethylation is a common phenomenon in cancer 4, 23 and an indicator of good prognosis in acute lymphoblastic leukemia, 24 whereas it is a poor prognostic marker in breast cancer. 25 In AML, a decrease in global DNA methylation at relapse compared with diagnosis was observed in one study; however, these patients were selected on the grounds of having relapsed, which makes comparisons with our study difficult. 26 Mechanistically, global DNA hypomethylation may have a role in cancerogenesis through increased genomic instability, activation of oncogenes or retrotransposons. 27 The reason for the increased CR rates in patients with global hypomethylation observed in our study is unclear. There were somewhat fewer patients with adverse and more with favorable karyotype in the hypomethylated group, but these differences were not significant and were not retained in multivariate analysis. Recent data show increased global LUMA methylation in cell lines resistant to daunorubicin in comparison to their sensitive counterparts (own unpublished data), suggestive of a possible association with drug resistance. Further studies on this matter are warranted, especially to determine whether demethylating agents could sensitize resistant cells to conventional cytostatic drugs in AML, which has already been shown in vitro in other cancers. 28, 29 Furthermore, our analysis showed that global LUMA methylation data were prognostically important mainly in patients younger than 65 years. One explanation for this could be that intra-individual methylation variation accelerates with increasing age, which could affect both global and gene-specific methylation and hence make cross-sectional analyses such as ours less predictive in an older population. 30, 31 Differences in correlations with CR versus survival for prognostic factors are not uncommon in AML. Although obviously correlated, CR and survival represent somewhat different effects on the disease, which may explain the differences in outcome on these variables. We also found an inverse relationship between global methylation levels as measured by LUMA and CpG island-related genome-wide methylation levels as measured by Illumina HumanMethylation 27. LUMA analysis is based on the HpaII/MspI recognition sequence, 5 0 -CCGG-3 0 , which are fairly well interspersed through the genome. Approximately 50% of the CCGG sites are located in repetitive DNA sequences and 50% in unique sequence, 32 and even though they are accumulated at CpG islands, CpG islands only comprise about 1% of the genome. 31 Therefore, methylation Prognostic implications of DNA methylation in AML S Deneberg et al effects measured by LUMA is dominated by methylation outside of CpG islands, a fact that is also supported by its linear correlation with LINE-1 analysis. 16, 33 In contrast, the Illumina HumanMethylation27 assay almost exclusively investigates promoter-associated CpG islands proximal to known genes. Our interpretation is that there is a correlation between DNA hypomethylation in non-promoter DNA regions and increased methylation of CpG islands, a phenomenon previously described as a tumor-associated process in solid tumors but not previously in leukemia. 34, 35 Previous studies evaluating the relationship between methylation of the p15 promoter and survival in AML show conflicting results. Methylation of the p15 promoter has been associated with poor 9, 22 prognosis whereas some studies have failed to show any association with prognosis. 7, 36 Other studies support our findings, associating more methylation with better prognosis in AML. 37 This concept has been shown previously in colon cancer, in which the CpG island methylated phenotype subtype is associated with improved survival. 38 Our study shows a statistically significant association between p15 promoter methylation and improved DFS and OS, independently of other risk factors. We believe that the diverging results in the studies are due to differences in the selection of patients and methylation analysis techniques. Recent data, including our own observations, have illustrated the differences between MDS, MDS-AML and de novo AML regarding methylation patterns. [39] [40] [41] These data suggest that MDS and AML have different methylation patterns and thus should be analyzed separately in this kind of study. The use of different methylation assays could be exemplified by the study by Shimamoto et al., 9 in which methylation was detected by methylation-specific PCR. DGGE is less sensitive than methylation-specific PCR but most likely better reflects the general methylation levels in the highly variable promoter region. In addition, methylation-specific PCR may pick up very low levels of methylation that are not physiologically relevant. Our AML cohort was defined with respect to the cytogenetic profile as well as to the mutational status of FLT3, NPM1, CEBPA and NRAS. There were surprisingly few correlations between the genetic characteristics of the patients and the methylation pattern, as analyzed by gene-specific methylation and global methylation by LUMA, suggesting that DNA methylation is a phenomenon that occurs independently of genetic subgroup.
In conclusion, in this study, we evaluated a genetically and clinically well-defined, large AML cohort with respect to genespecific and global methylation. Our results show that low global DNA methylation levels correlate with an improved CR rate and that methylation of p15 correlates with better DFS and OS independently of other molecular and cytogenetic prognostic factors. We also show an inverse correlation between global DNA methylation and genome-wide promoter methylation and an association between the number of hypermethylated CpG sites measured genome-wide by the Illumina HumanMethylation27 array and prognosis. We suggest that methylation patterns may be used as new tools to predict outcome in AML patients and that there are potentially new subgroups of AML that could be defined by methylation patterns. Still, further studies on the prognostic and biological role of DNA methylation in AML are warranted.
